Abstract
Impaired clearance of amyloid-β (Aβ) is a major pathogenic event for Alzheimer's disease (AD). Aβ depositions in brain parenchyma as senile plaques and along cerebrovasculature as cerebral amyloid angiopathy (CAA) are hallmarks of AD. A major pathway that mediates brain Aβ clearance is the cerebrovascular system where Aβ is eliminated through the blood-brain barrier (BBB) and/or degraded by cerebrovascular cells along the interstitial fluid drainage pathway. An Aβ clearance receptor, the low-density lipoprotein receptor-related protein 1 (LRP1), is abundantly expressed in cerebrovasculature, in particular in vascular smooth muscle cells. Here, we demonstrate that Aβ can be cleared locally in the cerebrovasculature by an LRP1-dependent endocytic pathway in smooth muscle cells. Conditional deletion of Lrp1 in vascular smooth muscle cell in amyloid model APP/PS1 mice accelerated brain Aβ accumulation and exacerbated Aβ deposition as amyloid plaques and CAA without affecting Aβ production. These studies establish critical functions of the cerebrovasculature system in Aβ metabolism and identify a new pathway involved in the pathogenesis of both AD and CAA.
Introduction
Alzheimer’s Disease (AD) is increasingly characterized by a failure in the clearance of Amyloid-β (Aβ) rather than solely its overproduction. Aβ typically accumulates in the brain parenchyma as senile plaques and within blood vessel walls as Cerebral Amyloid Angiopathy (CAA). While research has historically focused on the blood-brain barrier (BBB) and endothelial LRP1-mediated transport, the role of vascular smooth muscle cells (VSMCs) in Aβ metabolism has remained less clear. This study investigates whether VSMCs actively clear Aβ via an LRP1-dependent pathway.
Methods
The researchers utilized both human cell cultures and transgenic mouse models to dissect the role of LRP1 in VSMCs:
- In Vitro Studies: Human Brain Vascular Smooth Muscle Cells (HBVSMCs) were treated with siRNA to silence LRP1. The cells' ability to internalize and degrade Aβ40 and Aβ42 was measured using flow cytometry and confocal microscopy.
- In Vivo Models: A conditional knockout mouse ($smLrp1^{-/-}$) was generated, specifically deleting LRP1 in smooth muscle cells. These mice were crossed with the APP/PS1 amyloid model to observe the impact on plaque and CAA formation.
- Biochemical Analysis: Aβ levels were quantified via ELISA, and protein expression was assessed through Western blotting. Importantly, the researchers monitored Aβ-producing enzymes (BACE1, APP) and other degrading enzymes (neprilysin, IDE) to ensure observed changes were due to clearance deficits.
Key Results
The study identifies VSMCs as active scavengers that internalize Aβ for lysosomal degradation. LRP1 acts as the primary receptor for this uptake. In cell culture experiments, silencing LRP1 significantly increased the levels of Aβ40 and Aβ42 in the extracellular media, confirming a reduction in local clearance.
In vivo, the loss of VSMC-LRP1 led to a significant increase in endogenous Aβ levels in $smLrp1^{-/-}$ mice. When crossed with the APP/PS1 model, these mice exhibited a massive acceleration of both cortical amyloid plaques and CAA by 13–14 months of age. Crucially, the levels of Aβ-producing and other degrading enzymes remained stable, pinpointing the pathology to a specific deficit in VSMC-mediated clearance.
Discussion and Implications
These findings suggest a shift in how we view brain Aβ clearance. Rather than relying solely on systemic transport across the BBB, the brain utilizes local "garbage disposal" units in the form of VSMCs. The study also highlights a link between oxidative stress (via $H_2O_2$) and the downregulation of LRP1, suggesting a mechanism by which vascular risk factors contribute to AD.
Future research may explore whether upregulating LRP1 in VSMCs—perhaps through pharmacological agents like rifampicin—could serve as a therapeutic strategy to enhance Aβ clearance and mitigate the progression of AD and CAA.
Summary updated